Mandating h1n1 vaccine
Mandating h1n1 vaccine - jason priestly dating
(Note that some people have questioned a relationship between thimerosal and autism, but a 2004 review by the Institute of Medicine found no association, and subsequent studies have supported this conclusion. Individuals with the highest priority, as listed above, should be vaccinated first, but stringency of methods to restrict vaccine use is unclear.
The results showed that absolute efficacy against influenza A was 72% for the killed virus vaccine (IM injection) vs 29% for live virus vaccine (nasal sniff).
A double-blind, placebo-controlled trial comparing the LAIV vaccine and the inactivated influenza virus vaccine was conducted in 2007-2008 when influenza A (H3N2) accounted for 91% of influenza cases and type B accounted for 9%.
There were 1952 participants ages 18-49 years assigned to receive the inactivated vaccine (or placebo) by IM injection or the live virus vaccine (or placebo) by nasal spray.
The most common side effect with the killed virus vaccine is soreness at the injection site.
Concurrent administration with other vaccines is The second vaccine is a live attenuated influenza (LAIV), which is given intranasally. It is produced the same way as the LAIV that is used for seasonal flu.
Younger children had the expected reduced response and will require 2 doses separated by at least 21 days. record_id=10997 Accessed October 5, 2009.) The H1N1 vaccine will not prevent seasonal flu, and seasonal flu vaccine will not prevent 2009 H1N1 influenza.
Infants younger than 6 months are too young for influenza vaccines. Children 6 months to 9 years of age should receive 2 doses separated by 3 weeks.
The method was a case-cohort analysis using surveillance data from 8 states for May-June 2009, for cases of laboratory-confirmed pandemic H1N1 influenza infection in adults older than 18 years of age.
Seasonal flu vaccine coverage rates for those states were estimated by the Behavioral Risk Factor Surveillance Survey (BRFSS).
The results showed that vaccination rate to seasonal flu in patients with 2009 influenza A (H1N1) was 30%, compared with 29% in the population cohort.
Vaccination effectiveness against 2009 (H1N1) was estimated at -10%.
It is expected that the LAIV for H1N1 influenza will be as safe and effective as the LAIV for seasonal flu.